
Vaccine trials for children aged 5-11 should be more comprehensive. For this reason, studies of the Pfizer-Biontech vaccine and the Moderna vaccine within this group will now be expanded, writes the New York Times.
The US Food and Drug Administration have called for this to happen, asking vaccine companies to include 3,000 people in the trials, which is twice as many as originally planned, according to the NYT.
Already a subscriber? Log in.
Read the whole article
Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
- Access all locked articles
- Receive our daily newsletters
- Access our app